Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing Jun 28, 2023
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy Jun 15, 2023
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program Jun 15, 2023
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects Jun 13, 2023
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy Jun 12, 2023
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 23, 2023
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 22, 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 May 19, 2023
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 15, 2023
